162 related articles for article (PubMed ID: 23344868)
1. Immunohistochemical expression of ErbB2 in adamantinomatous craniopharyngiomas: a possible target for immunotherapy.
Zuhur SS; Tanik C; Erol RS; Musluman AM; Kabukcuoglu F; Altuntas Y
Turk Neurosurg; 2013; 23(1):55-60. PubMed ID: 23344868
[TBL] [Abstract][Full Text] [Related]
2. Comparative immunohistochemical expression of β-catenin, EGFR, ErbB2, and p63 in adamantinomatous and papillary craniopharyngiomas.
Esheba GE; Hassan AA
J Egypt Natl Canc Inst; 2015 Sep; 27(3):139-45. PubMed ID: 26198262
[TBL] [Abstract][Full Text] [Related]
3. Possible linkage between specific histological structures and aberrant reactivation of the Wnt pathway in adamantinomatous craniopharyngioma.
Kato K; Nakatani Y; Kanno H; Inayama Y; Ijiri R; Nagahara N; Miyake T; Tanaka M; Ito Y; Aida N; Tachibana K; Sekido K; Tanaka Y
J Pathol; 2004 Jul; 203(3):814-21. PubMed ID: 15221941
[TBL] [Abstract][Full Text] [Related]
4. Expression of aberrant beta-catenin and impaired p63 in craniopharyngiomas.
Cao J; Lin JP; Yang LX; Chen K; Huang ZS
Br J Neurosurg; 2010 Jun; 24(3):249-56. PubMed ID: 20128632
[TBL] [Abstract][Full Text] [Related]
5. Nuclear beta-catenin accumulation associates with epithelial morphogenesis in craniopharyngiomas.
Buslei R; Hölsken A; Hofmann B; Kreutzer J; Siebzehnrubl F; Hans V; Oppel F; Buchfelder M; Fahlbusch R; Blümcke I
Acta Neuropathol; 2007 May; 113(5):585-90. PubMed ID: 17221204
[TBL] [Abstract][Full Text] [Related]
6. Study of β-catenin and BRAF alterations in adamantinomatous and papillary craniopharyngiomas: mutation analysis with immunohistochemical correlation in 54 cases.
Malgulwar PB; Nambirajan A; Pathak P; Faruq M; Suri V; Sarkar C; Jagdevan A; Sharma BS; Sharma MC
J Neurooncol; 2017 Jul; 133(3):487-495. PubMed ID: 28500561
[TBL] [Abstract][Full Text] [Related]
7. Expression of enamel proteins and LEF1 in adamantinomatous craniopharyngioma: evidence for its odontogenic epithelial differentiation.
Sekine S; Takata T; Shibata T; Mori M; Morishita Y; Noguchi M; Uchida T; Kanai Y; Hirohashi S
Histopathology; 2004 Dec; 45(6):573-9. PubMed ID: 15569047
[TBL] [Abstract][Full Text] [Related]
8. Does the calcification of adamantinomatous craniopharyngioma resemble the calcium deposition of osteogenesis/odontogenesis?
Song-Tao Q; Xiao-Rong Y; Jun P; Yong-Jian D; Jin L; Guang-Long H; Yun-Tao L; Jian R; Xiang-Zhao L; Jia-Ming X
Histopathology; 2014 Feb; 64(3):336-47. PubMed ID: 24387671
[TBL] [Abstract][Full Text] [Related]
9. Common mutations of beta-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region.
Buslei R; Nolde M; Hofmann B; Meissner S; Eyupoglu IY; Siebzehnrübl F; Hahnen E; Kreutzer J; Fahlbusch R
Acta Neuropathol; 2005 Jun; 109(6):589-97. PubMed ID: 15891929
[TBL] [Abstract][Full Text] [Related]
10. Impact of the Canonical Wnt Pathway Activation on the Pathogenesis and Prognosis of Adamantinomatous Craniopharyngiomas.
Jucá CEB; Colli LM; Martins CS; Campanini ML; Paixão B; Jucá RV; Saggioro FP; de Oliveira RS; Moreira AC; Machado HR; Neder L; Antonini SR; de Castro M
Horm Metab Res; 2018 Jul; 50(7):575-581. PubMed ID: 29625497
[No Abstract] [Full Text] [Related]
11. Differential Expression of Stem Cell Markers in Human Adamantinomatous Craniopharyngioma and Pituitary Adenoma.
Chang CV; Araujo RV; Cirqueira CS; Cani CM; Matushita H; Cescato VA; Fragoso MC; Bronstein MD; Zerbini MC; Mendonca BB; Carvalho LR
Neuroendocrinology; 2017; 104(2):183-193. PubMed ID: 27161333
[TBL] [Abstract][Full Text] [Related]
12. Nuclear beta-catenin accumulation as reliable marker for the differentiation between cystic craniopharyngiomas and rathke cleft cysts: a clinico-pathologic approach.
Hofmann BM; Kreutzer J; Saeger W; Buchfelder M; Blümcke I; Fahlbusch R; Buslei R
Am J Surg Pathol; 2006 Dec; 30(12):1595-603. PubMed ID: 17122517
[TBL] [Abstract][Full Text] [Related]
13. Aberrant membranous expression of β-catenin predicts poor prognosis in patients with craniopharyngioma.
Li Z; Xu J; Huang S; You C
Ann Diagn Pathol; 2015 Dec; 19(6):403-8. PubMed ID: 26547438
[TBL] [Abstract][Full Text] [Related]
14. Sonic Hedgehog pathway is upregulated in adamantinomatous craniopharyngiomas.
Gomes DC; Jamra SA; Leal LF; Colli LM; Campanini ML; Oliveira RS; Martinelli CE; Elias PC; Moreira AC; Machado HR; Saggioro F; Neder L; Castro M; Antonini SR
Eur J Endocrinol; 2015 May; 172(5):603-8. PubMed ID: 25693592
[TBL] [Abstract][Full Text] [Related]
15. Tumour cell migration in adamantinomatous craniopharyngiomas is promoted by activated Wnt-signalling.
Hölsken A; Buchfelder M; Fahlbusch R; Blümcke I; Buslei R
Acta Neuropathol; 2010 May; 119(5):631-9. PubMed ID: 20131060
[TBL] [Abstract][Full Text] [Related]
16. Interleukin‑6 induces an epithelial‑mesenchymal transition phenotype in human adamantinomatous craniopharyngioma cells and promotes tumor cell migration.
Zhou J; Zhang C; Pan J; Chen L; Qi ST
Mol Med Rep; 2017 Jun; 15(6):4123-4131. PubMed ID: 28487953
[TBL] [Abstract][Full Text] [Related]
17. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target.
Apps JR; Carreno G; Gonzalez-Meljem JM; Haston S; Guiho R; Cooper JE; Manshaei S; Jani N; Hölsken A; Pettorini B; Beynon RJ; Simpson DM; Fraser HC; Hong Y; Hallang S; Stone TJ; Virasami A; Donson AM; Jones D; Aquilina K; Spoudeas H; Joshi AR; Grundy R; Storer LCD; Korbonits M; Hilton DA; Tossell K; Thavaraj S; Ungless MA; Gil J; Buslei R; Hankinson T; Hargrave D; Goding C; Andoniadou CL; Brogan P; Jacques TS; Williams HJ; Martinez-Barbera JP
Acta Neuropathol; 2018 May; 135(5):757-777. PubMed ID: 29541918
[TBL] [Abstract][Full Text] [Related]
18. PROP1 and CTNNB1 expression in adamantinomatous craniopharyngiomas with or without β-catenin mutations.
Cani CM; Matushita H; Carvalho LR; Soares IC; Brito LP; Almeida MQ; Mendonça BB
Clinics (Sao Paulo); 2011; 66(11):1849-54. PubMed ID: 22086512
[TBL] [Abstract][Full Text] [Related]
19. Drug priming enhances radiosensitivity of adamantinomatous craniopharyngioma via downregulation of survivin.
Stache C; Bils C; Fahlbusch R; Flitsch J; Buchfelder M; Stefanits H; Czech T; Gaipl U; Frey B; Buslei R; Hölsken A
Neurosurg Focus; 2016 Dec; 41(6):E14. PubMed ID: 27903123
[TBL] [Abstract][Full Text] [Related]
20. Cellular differentiation, secretory and proliferative activities of craniopharyngiomas.
Uematsu Y; Komai N; Tanaka Y; Shimizu M; Naka D; Yukawa S; Itakura T; Hayashi S
Noshuyo Byori; 1994; 11(1):43-50. PubMed ID: 7909255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
